Natural Investments LLC Decreases Stake in AbbVie Inc. $ABBV

Key Points

• Natural Investments LLC cut its AbbVie stake by 27.1%, selling 10,548 shares to hold 28,305 shares valued at about $6.47 million, making AbbVie 1.6% of its portfolio and its 13th-largest position.
• Senior insiders also sold recently (SVP David Ryan Purdue: 5,230 shares; EVP Perry C. Siatis: 22,381 shares), leaving corporate insiders with just 0.06% ownership.
• AbbVie has pipeline catalysts — strong Phase 2 data for ELAHERE and a licensing deal for pain assets (~$715–745M potential) — but the stock has pulled back amid valuation/technical pressure despite a consensus "Moderate Buy" and a roughly $253 target; the company pays a $1.73 quarterly dividend (~3.4% yield).

Natural Investments LLC reduced its stake in AbbVie Inc. (NYSE:ABBV - Free Report) by 27.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 28,305 shares of the company's stock after selling 10,548 shares during the period. AbbVie comprises 1.6% of Natural Investments LLC's investment portfolio, making the stock its 13th largest position. Natural Investments LLC's holdings in AbbVie were worth $6,467,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of ABBV. Wellington Management Group LLP increased its stake in AbbVie by 457.4% in the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company's stock worth $2,439,714,000 after purchasing an additional 8,646,424 shares during the period. Raymond James Financial Inc. grew its position in shares of AbbVie by 41.8% in the 2nd quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company's stock worth $1,733,222,000 after buying an additional 2,753,312 shares during the last quarter. Alliancebernstein L.P. grew its position in shares of AbbVie by 31.8% in the 3rd quarter. Alliancebernstein L.P. now owns 7,281,327 shares of the company's stock worth $1,685,918,000 after buying an additional 1,758,657 shares during the last quarter. Amundi grew its position in shares of AbbVie by 15.6% in the 3rd quarter. Amundi now owns 10,508,317 shares of the company's stock worth $2,418,909,000 after buying an additional 1,414,621 shares during the last quarter. Finally, Danske Bank A S bought a new stake in shares of AbbVie in the 3rd quarter worth approximately $279,609,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the sale, the senior vice president directly owned 2,654 shares of the company's stock, valued at approximately $619,868.24. This represents a 66.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president directly owned 38,137 shares in the company, valued at approximately $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.06% of the company's stock.

Wall Street Analyst Weigh In

ABBV has been the topic of a number of recent analyst reports. Sanford C. Bernstein reiterated a "market perform" rating on shares of AbbVie in a research report on Thursday, February 5th. Weiss Ratings reiterated a "hold (c)" rating on shares of AbbVie in a research report on Wednesday, January 21st. Cantor Fitzgerald cut their price objective on AbbVie from $250.00 to $240.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 8th. William Blair reiterated an "outperform" rating on shares of AbbVie in a research report on Monday, March 9th. Finally, Berenberg Bank set a $275.00 price objective on AbbVie in a research report on Tuesday, January 20th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, AbbVie presently has a consensus rating of "Moderate Buy" and a consensus target price of $253.00.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Late‑breaking Phase 2 data for mirvetuximab soravtansine‑gynx (ELAHERE) in platinum‑sensitive ovarian cancer showed strong activity (objective response rate ~62.7% in FRα ≥50% patients) with consistent safety, supporting broader use across the ovarian cancer continuum and raising upside for AbbVie’s oncology franchise. AbbVie Ovarian Cancer Data And Pain Deal Extend Long Term Story
• Positive Sentiment: AbbVie struck an exclusive global license (ex-China/HK/Macau) with Haisco for two acute pain assets in a deal reported as up to roughly $715–745M, adding late‑stage pain programs and diversifying AbbVie’s pipeline outside its core immunology and oncology businesses. Haisco’s shares reacted positively. AbbVie inks $745M deal with Chinese biotech Haisco for two acute pain assets
• Positive Sentiment: An analyst raised AbbVie’s price target to $249, signaling bullish analyst sentiment that could support upside if execution on new indications and the pain franchise continues. AbbVie NYSE: ABBV Price Target Raised to $249.00
• Neutral Sentiment: Coverage notes (Zacks) flag neuroscience (Botox, Vraylar) as a growth driver for Q1 revenue, which could help offset legacy product declines but is already anticipated by the Street. Will AbbVie's Neuroscience Franchise Aid Top-line Growth in Q1?
• Neutral Sentiment: Local reporting on an AbbVie Foundation donation to a university cancer center says the gift won’t affect clinical independence — largely a reputational/PR item rather than a financial driver. UCMed Administrators Say AbbVie Foundation Donation to New Cancer Center Will Not Infringe on Its Independence
• Negative Sentiment: Despite the positive data and deal news, the stock is trading lower—likely reflecting short‑term profit‑taking, stretched valuation (high P/E vs. peers) and technical pressure (shares below recent 50/200‑day moving averages), which can mute immediate upside. (Background market/technical context provided.)

AbbVie Stock Down 0.7%

NYSE ABBV opened at $206.40 on Tuesday. AbbVie Inc. has a twelve month low of $168.54 and a twelve month high of $244.81. The firm has a market capitalization of $364.94 billion, a PE ratio of 87.46, a P/E/G ratio of 0.75 and a beta of 0.38. The stock's 50 day moving average is $219.96 and its 200 day moving average is $223.96.

AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The company had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. During the same period in the previous year, the company posted $2.16 earnings per share. The firm's revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, research analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 3.4%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie's payout ratio is 293.22%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.